Stock Price Movement and Market Context
On 25 September 2026, Medico Remedies Ltd’s share price touched an intraday low of Rs.29.86, representing an 8.6% decline on the day and a notable 8.17% drop in the closing price. This fall extended a losing streak that has persisted for six consecutive trading sessions, during which the stock has shed approximately 15.92% of its value. The current price is substantially below the stock’s 52-week high of Rs.56.99, underscoring the extent of the recent correction.
The stock’s performance today lagged behind its Pharmaceuticals & Biotechnology sector peers by 6.85%, highlighting relative weakness within its industry group. Furthermore, Medico Remedies is trading below all key moving averages — including the 5-day, 20-day, 50-day, 100-day, and 200-day averages — signalling a sustained bearish trend from a technical perspective.
In comparison, the broader market benchmark, the Sensex, showed modest gains of 0.06% to close at 73,622.00 points after a flat opening. However, the Sensex itself remains 2.82% above its own 52-week low of 71,545.81 and is trading below its 50-day moving average, with the 50-day average positioned below the 200-day average, indicating a cautious market environment. Mega-cap stocks led the market’s slight advance, contrasting with the micro-cap status of Medico Remedies.
Long-Term and Recent Performance Metrics
Over the past year, Medico Remedies has delivered a total return of -38.57%, significantly underperforming the Sensex’s -9.28% return over the same period. This underperformance extends beyond the last 12 months, with the stock also lagging the BSE500 index across one-year, three-month, and three-year timeframes. The company’s Mojo Score currently stands at 43.0, with a Mojo Grade of ‘Sell’ as of 15 September 2026, a downgrade from the previous ‘Hold’ rating.
Financial Performance and Operational Highlights
Despite the stock’s price weakness, Medico Remedies has demonstrated some positive financial trends. The company reported net sales of Rs.184.89 crores for the nine months ended, reflecting a robust growth rate of 55.32%. Profit after tax (PAT) for the same period stood at Rs.11.25 crores, up 28.13% year-on-year. Operating profit has grown at an annualised rate of 36.46%, and the company has declared positive results for six consecutive quarters.
Medico Remedies maintains a strong balance sheet with a low Debt to EBITDA ratio of 0.82 times, indicating a manageable debt burden relative to earnings. Its return on capital employed (ROCE) is 13.6%, and the enterprise value to capital employed ratio is 3.2, suggesting an attractive valuation compared to peers’ historical averages. The company’s PEG ratio of 0.6 further reflects earnings growth outpacing its price decline over the past year.
Technical Indicators and Market Sentiment
Technical analysis reveals predominantly bearish signals across multiple timeframes. The Moving Average Convergence Divergence (MACD) indicator is bearish on both weekly and monthly charts. The Relative Strength Index (RSI) is bearish on a weekly basis, while monthly RSI shows no clear signal. Bollinger Bands and the Know Sure Thing (KST) indicator also reflect bearish momentum weekly and monthly. Dow Theory assessments indicate mild bearishness, and the On-Balance Volume (OBV) is mildly bullish weekly but mildly bearish monthly, suggesting some divergence between price and volume trends.
Shareholding and Market Capitalisation
The majority shareholding in Medico Remedies remains with promoters, consistent with previous disclosures. The company is classified as a micro-cap stock, which often entails higher volatility and sensitivity to market fluctuations compared to larger capitalisation peers.
Summary of Key Data Points
• New 52-week low price: Rs.29.86 (25 September 2026)
• Day’s intraday low: Rs.29.86 (-8.6%)
• Six consecutive days of price decline, total loss of 15.92% in this period
• One-year return: -38.57% versus Sensex -9.28%
• Mojo Score: 43.0, Mojo Grade: Sell (downgraded from Hold on 15 September 2026)
• Debt to EBITDA ratio: 0.82 times
• Net sales growth (9M): 55.32% to Rs.184.89 crores
• PAT growth (9M): 28.13% to Rs.11.25 crores
• ROCE: 13.6%
• Enterprise value to capital employed: 3.2
• PEG ratio: 0.6
Medico Remedies Ltd’s recent decline to a 52-week low reflects a combination of sustained price weakness and underperformance relative to sector and market benchmarks. While the company’s financial results show encouraging growth in sales and profits, the stock’s technical indicators and market positioning continue to signal caution. The micro-cap status and promoter majority ownership remain unchanged amid this challenging phase for the share price.
